Delivery Order SPE2DB22D2206-SPE2DB24FKB64

Award Date 8/29/24
Potential Completion Date 8/30/24
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,171,074 units of the pharmaceutical product Cefepime-Dextrose 2 GM/50 MLS. The contract has a ceiling value of $3,653.65 and an ultimate completion date of April 5, 2024. This delivery order contract is part of a larger $999,999,999.00 indefinite delivery contract (IDC) that Amerisourcebergen Drug Corp holds...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $8,407.50 firm-fixed-price contract is for the supply of Cefepime-Dextrose 2 GM/50 MLS, a critical pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the government to efficiently procure a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Cefepime-Dextrose 2 GM/50 MLS. The contract has a firm fixed price of $2,665.02 and a completion date of July 3, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,665.02 firm-fixed-price contract is for the delivery of the pharmaceutical product Cefepime-Dextrose 2 GM/50 MLS, with a period of performance through May 23, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with DLA Troop...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, and has a ceiling value of $2,665.02. The contract is a firm fixed price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,821.52, is for the provision of Cefepime-Dextrose 2 GM/50 MLS, a pharmaceutical product. The contract has an ultimate completion date of May 17, 2023 and is a Firm Fixed Price type contract. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CEFEPIME-DEXTROSE 1 GM/50 MLS, a type of prescription medication. The contract has a firm fixed price, non-set-aside designation, and a ceiling value of $2,286.48. The ultimate completion date for this delivery order is May 20, 2025. Amerisourcebergen Drug Corp is the prime...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, with a ceiling value of $14,307.57 and a period of performance through May 20, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has a ceiling value of $1,266.98 and provides the DLA with a variety of medical supplies and pharmaceutical products, including the drug Cefepime-Dextrose. The contract has an ultimate completion date of March 13, 2025 and is structured as a firm-fixed-price delivery order. This award is associated with a larger Indefinite...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, with a ceiling value of $4,184.38 and a completion date of May 28, 2025. The contract is a firm-fixed-price delivery order, without a set-aside designation, indicating open competition. AmerisourceBergen Drug Corporation holds a significant...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FKB64
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,565,634,020 units of Cefepime-Dextrose 2 GM/50 MLS. The delivery order is a firm fixed-price contract with a ceiling value of $10,167.08. It was issued under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and the ultimate completion date is August 30, 2024.

Generated 11/28/24, 9:24 AM